Short Title: Actuate 1801
GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.
Please note that we are only open to enrollment for Part 3 Arm B: Randomized Phase 2 Study of Gemcitabine/Nab-Paclitaxel Plus 9-ING-41 in Patients with Previously Untreated Metastatic Pancreatic Cancer.
Study Number:
Actuate 1801
Study Status:
Enrolling
Treatment Agent:
9-ING-41, Gemcitabine, Doxorubicin, Lomustine, Carboplatin, Nab paclitaxel, Paclitaxel, Irinotecan
National Clinical Trial Identified Number: NCT03678883
Disease:
Study Phase:
I/II
researchcancer@cooperhealth.edu
Phase I/II Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors
Hide from Search:
Off
Physician Name:
Department:
Short Title: SURVENT
The trial’s primary aim is to determine if patients undergoing endoscopic eradication therapy will demonstrate less neoplastic progression and a lower incidence of esophageal adenocarcinoma compared to patients undergoing surveillance.
Study Number:
SURVENT
Study Status:
Enrolled
Treatment Agent:
Not Applicable
National Clinical Trial Identified Number: NCT05753748
Disease:
Study Phase:
Not Applicable
researchcancer@cooperhealth.edu
A Multicenter Randomized Controlled Trial of Surveillance vs. Endoscopic Therapy for Barrett’s Esophagus with Low-grade Dysplasia
Hide from Search:
Off
Physician Name:
Department:
Short Title: SOROCk
This clinical trial studies how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk reduction for women with BRCA1 mutations.
Study Number:
CC008
Study Status:
Enrolling
Treatment Agent:
Not Applicable
National Clinical Trial Identified Number: NCT04251052
Disease:
Study Phase:
Not Applicable
ResearchCancer@CooperHealth.edu
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
Hide from Search:
Off
Physician Name:
Department:
Short Title: DECREASE
This phase II trial studies how well lower-dose chemotherapy plus radiation (chemoradiation) therapy works in comparison to standard-dose chemoradiation in treating patients with early-stage anal cancer. Drugs used in chemotherapy, such as mitomycin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy with radiation therapy may kill more tumor cells. This study may help doctors find out if lower-dose chemoradiation is as effective and has fewer side effects than standard-dose chemoradiation, which is the usual approach for treatment of this cancer type.
Study Number:
EA2182
Study Status:
Enrolling
Treatment Agent:
Capecitabine, Fluorouracil, Mitomycin
National Clinical Trial Identified Number: NCT04166318
Disease:
Study Phase:
II
researchcancer@cooperhealth.edu
A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma
Hide from Search:
Off
Physician Name:
Department:
